APA (7th ed.) Citation

Glaß, B., Hasenkamp, J., Wulf, G., Dreger, P., Pfreundschuh, M., Gramatzki, M., . . . Schmitz, N. (2014). Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): An open-label, randomised, phase 2 trial. The lancet. Oncology, 15(7), . https://doi.org/10.1016/S1470-2045(14)70161-5

Chicago Style (17th ed.) Citation

Glaß, Bertram, et al. "Rituximab After Lymphoma-directed Conditioning and Allogeneic Stem-cell Transplantation for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma (DSHNHL R3): An Open-label, Randomised, Phase 2 Trial." The Lancet. Oncology 15, no. 7 (2014). https://doi.org/10.1016/S1470-2045(14)70161-5.

MLA (9th ed.) Citation

Glaß, Bertram, et al. "Rituximab After Lymphoma-directed Conditioning and Allogeneic Stem-cell Transplantation for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma (DSHNHL R3): An Open-label, Randomised, Phase 2 Trial." The Lancet. Oncology, vol. 15, no. 7, 2014, https://doi.org/10.1016/S1470-2045(14)70161-5.